NCT01197092Unknown2 期
A Study Evaluating the Effects of a Regenerative Mitochondrial Medication on Physiological Parameters in Case of Diabetes Mellitus Type II
Center for Integrative Medicine, Germany2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- HbA1c Test (Glycated hemoglobin)
研究概览
简要总结
A treatment with the concept of mitochondrial medication developed by Dr Heinrich Kremer can demonstrably improve and successfully treat actual parameters of Diabetes Mellitus II as well as its risk factors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •men and women between the ages of 18 and 60
- •recently diagnosed Diabetes Type II (within the last 12 months)
排除标准
- •no orally-taken medication up to present
- •no insulin therapy
- •no diseases resulting from diabetes like Nephropathy, Neuropathy, Angiopathy or Retinopathy
- •fasting blood sugar values in the morning under 200mmol
- •sufficient production of insulin
结局指标
主要结局
HbA1c Test (Glycated hemoglobin)
时间窗: 4 month average
Laboratory test
次要结局
- Nutrient IgGs Panels (BiomedicalScreen)(4 month average)
- Insulin, Adiponectin, Leptin(4 month average)
- Potassium, selene, magnesium, zinc in whole blood(4 month average)
- Blood count(4 month average)
- Electrolytes(4 month average)
- Liver, pancreatic and kidney retention values(4 month average)
- Lipids: Cholesterol,Triglycerides(4 month average)
- Oxyd LDL (low-density lipoprotein cholesterol)(4 month average)
- Free lipids fasting(4 month average)
- Lipoprotein A(4 month average)
- Fibrinogen(4 month average)
- CRP (C Reactive protein)(4 month average)
- LDH-Isoenzymes (Lactate dehydrogenase)(4 month average)
- SHbG, full-testosterone (Androgen-Index)(4 month average)
- PlasminInhibitor I(4 month average)
- Vitamins B1,B2,B6,B 12, Vitamin D(4 month average)
- Homocysteins(4 month average)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
The Use of a Mitochondrial Enhancement Treatment in Bipolar DisorderBipolar DepressionNCT00719706Mclean Hospital40
已完成
4 期
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)Primary Open-Angle Glaucoma (POAG)NCT06437639Pharmasoft80
已完成
不适用
The Effects of a Novel Mitochondrial Substrate Supplement on Exercise Performance and Cognitive FunctionExercise PerformanceCognitive FunctionNCT06374641University of Exeter40
终止
2 期
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisNCT00219908Rennes University Hospital124
No Longer Available
不适用
A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on DialysisAnemiaNCT01892202Hoffmann-La Roche